Prostate Cancer News and Research

Latest Prostate Cancer News and Research

FGF protein may play key role in breast and prostate cancer, shows research

Simply put, cancer is caused by mutations to genes within a cell that lead to abnormal cell growth. Finding out what causes that genetic mutation has been the holy grail of medical science for decades.

13 Aug 2015

New MRI contrast agent detects tiny breast cancer tumors, micrometastases

Researchers at Case Western Reserve University have developed a magnetic resonance imaging (MRI) contrast agent that detects much smaller aggressive breast cancer tumors and micrometastases than current agents can identify.

13 Aug 2015

UNMCC receives NCI Comprehensive Cancer Center designation for cancer treatment, research programs

The University of New Mexico Cancer Center has been awarded the highest designation and rating in the United States for cancer treatment and research programs. It has received the National Cancer Institute's "NCI Comprehensive Cancer Center" designation, identifying it as one of the leading cancer centers in the nation and the only such cancer center in New Mexico.

13 Aug 2015

New approach may offer improved way to detect early breast cancer

Researchers have shown that magnetic resonance imaging (MRI) can detect the earliest signs of breast cancer recurrence and fast-growing tumors. Their approach detects micromestastases, breakaway tumor cells with the potential to develop into dangerous secondary breast cancer tumors elsewhere in the body.

12 Aug 2015

Researcher study potential biomarker to determine patients at risk for aggressive breast cancer

Biomarkers are an important part in detecting certain cancers such as the BRCA gene in breast cancer and the PSA antigen in prostate cancer. They are easy to identify in a blood test and can help in diagnosing and giving a prognosis.

12 Aug 2015

Cost of radiation therapy varies widely among Medicare patients with cancer

Cost of radiation therapy among Medicare patients varied most widely because of factors unrelated to a patient or that person's cancer, report University of California, San Diego School of Medicine researchers in the Journal of Oncology Practice.

12 Aug 2015

Aeterna Zentaris reports that DSMB scheduled to close second interim analysis of ZoptEC Phase 3 trial in early October

Aeterna Zentaris Inc. today announced that the independent Data and Safety Monitoring Board for the pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) study with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer, will complete a pre-specified second interim efficacy and safety analysis of the compound in early October 2015.

11 Aug 2015

Clinical study shows two-drug combination can prolong survival in men with metastatic prostate cancer

Newly diagnosed patients with metastatic, hormone-sensitive prostate cancer gained a dramatic survival benefit when started on two drugs simultaneously, rather than delaying the second drug until the cancer began to worsen, according to results of a clinical trial led by a Dana-Farber Cancer Institute scientist.

6 Aug 2015

Johns Hopkins researchers report on more effective way to spot patients at risk of septic shock

For a patient with sepsis - which kills more Americans every year than AIDS and breast and prostate cancer combined - hours can make the difference between life and death.

6 Aug 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.

5 Aug 2015

Research: Failure to control early, localized prostate cancer leads to poor clinical outcome

Failure to control early, localized prostate cancer results in a poor clinical outcome, according to research published in the International Journal of Radiation Oncology Biology Physics.

4 Aug 2015

BRCA gene mutations and ovarian cancer: an interview with Dr Matulonis, Harvard Medical School

The BRCA gene encodes for the BRCA proteins, BRCA1 and BRCA2. These proteins are very important in repairing DNA, which they do by correcting double-stranded breaks.

2 Aug 2015

Prostate cancer discovery may improve treatment strategies

Scientists from Cancer Research UK have discovered that there are five different types of prostate cancer and have found a way of distinguishing between them. These findings could change how the condition is treated, providing more effective therapies where they are needed the most.

30 Jul 2015

Cancer Research UK scientists identify five distinct types of prostate cancer

Cancer Research UK scientists have for the first time identified that there are five distinct types of prostate cancer and found a way to distinguish between them, according to a landmark study published today in EBioMedicine.

30 Jul 2015

Moffitt researchers analyze participation rate of patients in pharmacogenomic trials

Cancer therapy has evolved from a "one-size-fits-all" type of treatment plan to a personalized approach based on a patient's type of cancer, the protein and genetic markers found in their tumors and their response to therapy. Important aspects of the personalized approach are pharmacogenomic studies that analyze associations between genetic variations and patient drug responses.

29 Jul 2015

Moffitt researchers find cancer healthcare disparities in LGBTQ community

The Lesbian, Gay, Bisexual, Transgender/Transsexual, Queer/Questioning (LGBTQ) community is a growing and medically-underserved minority population in the United States, with 3 to 12 percent of the population estimated to identify as LGBTQ.

29 Jul 2015

German life sciences entrepreneurs granted option to develop Aeterna Zentaris’ oral allogenic tumor vaccine technology

Aeterna Zentaris Inc. today announced that it has granted to German life sciences entrepreneurs with a proven track-record of funding the development and commercialization of biotechnology, an option to license the Company's live recombinant oral allogenic tumor vaccine technology, including AEZS-120, the most advanced product candidate for prostate cancer which is ready to enter a Phase 1 clinical trial.

28 Jul 2015

VolitionRx selects Global Specimen Solutions to support U.S. market entry of NuQ colorectal cancer tests

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has engaged the services of a specialty specimen management clinical research organization, Global Specimen Solutions, Inc., to support initial U.S. market entry of its NuQ colorectal cancer tests.

28 Jul 2015

ESSA Pharma receives final approval to start trading on Toronto Stock Exchange

ESSA Pharma Inc. is pleased to announce that it has received final approval for its common shares to be listed and commence trading on the Toronto Stock Exchange.

28 Jul 2015

Prostate cancer patients more likely to receive medical care matched to level of risk

After decades of overtreatment for low-risk prostate cancer and inadequate management of its more aggressive forms, patients are now more likely to receive medical care matched to level of risk, according to a study by researchers at UC San Francisco.

25 Jul 2015

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

FGF protein may play key role in breast and prostate cancer, shows research

New MRI contrast agent detects tiny breast cancer tumors, micrometastases

UNMCC receives NCI Comprehensive Cancer Center designation for cancer treatment, research programs

New approach may offer improved way to detect early breast cancer

Researcher study potential biomarker to determine patients at risk for aggressive breast cancer

Cost of radiation therapy varies widely among Medicare patients with cancer

Aeterna Zentaris reports that DSMB scheduled to close second interim analysis of ZoptEC Phase 3 trial in early October

Clinical study shows two-drug combination can prolong survival in men with metastatic prostate cancer

Johns Hopkins researchers report on more effective way to spot patients at risk of septic shock

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

Research: Failure to control early, localized prostate cancer leads to poor clinical outcome

BRCA gene mutations and ovarian cancer: an interview with Dr Matulonis, Harvard Medical School

Prostate cancer discovery may improve treatment strategies

Cancer Research UK scientists identify five distinct types of prostate cancer

Moffitt researchers analyze participation rate of patients in pharmacogenomic trials

Moffitt researchers find cancer healthcare disparities in LGBTQ community

German life sciences entrepreneurs granted option to develop Aeterna Zentaris’ oral allogenic tumor vaccine technology

VolitionRx selects Global Specimen Solutions to support U.S. market entry of NuQ colorectal cancer tests

ESSA Pharma receives final approval to start trading on Toronto Stock Exchange

Prostate cancer patients more likely to receive medical care matched to level of risk

What to know about prostate cancer eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in